Drug Approval | November 30, 2022
AstraZeneca’s Dapagliflozin receives CDSCO approval
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against Covid-19
The company has started manufacturing the Sputnik Light vaccine
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)